NO20083000L - Tetomilast polymorfer - Google Patents

Tetomilast polymorfer

Info

Publication number
NO20083000L
NO20083000L NO20083000A NO20083000A NO20083000L NO 20083000 L NO20083000 L NO 20083000L NO 20083000 A NO20083000 A NO 20083000A NO 20083000 A NO20083000 A NO 20083000A NO 20083000 L NO20083000 L NO 20083000L
Authority
NO
Norway
Prior art keywords
powder
ray diffraction
diffraction spectrum
crystal
tetomilast
Prior art date
Application number
NO20083000A
Other languages
English (en)
Inventor
Satoshi Aoki
Kenji Nakaya
Masahiro Sota
Masashi Ishigami
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38069222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083000(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20083000L publication Critical patent/NO20083000L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en tetomilast krystall som er industrielt enkelt å fremstille i en stort volum. (1) En tetomilast hydratkrystall som har et pulverrøntgendiffraksjonsspekter som er i det vesentlige det samme som pulverrøntgendiffraksjonsspekteret som er vist i fig. 2; (2) en vannfri tetomilast type A krystall som har et pulverrøntgendiffraksjonsspekter som er i det vesentlige det samme som pulverrøntgendiffraksjonsspekteret vist i fig. 4; (3) en vannfri tetomilast type C krystall som har et pulverrøntgendiffraksjonsspekter som er i det vesentlige det samme som pulverrøntgendiffraksjonsspekteret vist i fig. 8; (4) en tetomilast acetonitril solvatkrystall som har et pulverrøntgendiffraksjonsspekter som er i det vesentlige det samme som pulverrøntgendiffraksjonsspektret vist i fig. 10; og (5) en blanding som består av den ovenfor nevnte vannfrie tetomilast type A krystallen og en vannfri tetomilast type B krystall. Disse krystallene er stabile overfor varme og fuktighet og er også svært tilfredsstillende når det gjelder desintegreringsegenskaper og oppløsningsegenskaper for tabletter. Følgelig blir disse krystallene foretrukket anvendt som farmasøytiske sammensetninger.
NO20083000A 2006-03-17 2008-07-07 Tetomilast polymorfer NO20083000L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006075307 2006-03-17
PCT/JP2007/055931 WO2007119496A1 (en) 2006-03-17 2007-03-15 Tetomilast polymorphs

Publications (1)

Publication Number Publication Date
NO20083000L true NO20083000L (no) 2008-09-30

Family

ID=38069222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083000A NO20083000L (no) 2006-03-17 2008-07-07 Tetomilast polymorfer

Country Status (26)

Country Link
US (4) US8501949B2 (no)
EP (4) EP1999128B1 (no)
JP (2) JP4182363B2 (no)
KR (6) KR101168630B1 (no)
CN (4) CN102174044B (no)
AR (1) AR059911A1 (no)
AT (1) ATE476433T1 (no)
AU (1) AU2007239906B2 (no)
BR (1) BRPI0706224A2 (no)
CA (4) CA2725810C (no)
CY (3) CY1111046T1 (no)
DE (1) DE602007008212D1 (no)
DK (3) DK2311832T3 (no)
ES (3) ES2390957T3 (no)
IL (4) IL192237A (no)
MY (2) MY151343A (no)
NO (1) NO20083000L (no)
PH (1) PH12015502374A1 (no)
PL (3) PL2311832T3 (no)
PT (3) PT2206711E (no)
RU (2) RU2441002C2 (no)
SG (4) SG172707A1 (no)
SI (3) SI1999128T1 (no)
TW (1) TWI394753B (no)
WO (1) WO2007119496A1 (no)
ZA (2) ZA200805235B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186605B2 (en) 2016-10-06 2021-11-30 Kyowa Hakko Bio Co., Ltd. Crystal of cytidine diphosphate choline and production method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS216535B2 (en) * 1978-10-16 1982-11-26 Lilly Co Eli Fungicide means and means for regulation of the water plants growth and method of making the active substances
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
DK0934937T3 (da) * 1990-11-30 2002-04-02 Otsuka Pharma Co Ltd Azolderivater som superoxidradikalinhibitor
JP4300373B2 (ja) 1996-09-30 2009-07-22 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP4336913B2 (ja) 1999-02-12 2009-09-30 大塚製薬株式会社 アミド誘導体の製造方法
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE60206391T2 (de) * 2001-07-24 2006-07-13 Otsuka Pharmaceutical Co., Ltd. Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen
JP3713577B2 (ja) 2001-07-24 2005-11-09 大塚製薬株式会社 慢性閉塞性肺疾患治療薬
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
CA2550726A1 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms

Also Published As

Publication number Publication date
CY1113262T1 (el) 2016-04-13
ZA201001687B (en) 2010-11-24
EP2311832A1 (en) 2011-04-20
IL214252A0 (en) 2011-08-31
MY151343A (en) 2014-05-15
SG172708A1 (en) 2011-07-28
SI1999128T1 (sl) 2010-12-31
JP5197196B2 (ja) 2013-05-15
PT2206711E (pt) 2012-08-31
JP2008285498A (ja) 2008-11-27
SG10201408225VA (en) 2015-01-29
ES2348630T3 (es) 2010-12-10
CA2725698A1 (en) 2007-10-25
KR20130003041A (ko) 2013-01-08
SG172706A1 (en) 2011-07-28
CN102174046B (zh) 2013-12-25
CA2725810A1 (en) 2007-10-25
AR059911A1 (es) 2008-05-07
CA2725810C (en) 2013-01-22
PL1999128T3 (pl) 2010-12-31
EP2206711A2 (en) 2010-07-14
PT2311832E (pt) 2012-08-30
KR20110087350A (ko) 2011-08-02
ES2390926T3 (es) 2012-11-19
KR20110136902A (ko) 2011-12-21
IL214253A0 (en) 2011-08-31
US20150352095A1 (en) 2015-12-10
CY1111046T1 (el) 2015-06-11
JP2007277235A (ja) 2007-10-25
CA2725649C (en) 2013-05-14
US20140113937A1 (en) 2014-04-24
CN101365697B (zh) 2011-11-23
ES2390957T3 (es) 2012-11-20
CN102174045A (zh) 2011-09-07
IL214254A0 (en) 2011-08-31
CA2725649A1 (en) 2007-10-25
HK1159079A1 (en) 2012-07-27
DK1999128T3 (da) 2010-11-08
SI2311832T1 (sl) 2012-12-31
SG172707A1 (en) 2011-07-28
EP2206711B1 (en) 2012-08-22
HK1124062A1 (en) 2009-07-03
AU2007239906B2 (en) 2010-07-29
RU2408597C2 (ru) 2011-01-10
KR101083611B1 (ko) 2011-11-16
CN102174044B (zh) 2014-02-26
TWI394753B (zh) 2013-05-01
EP2206711A3 (en) 2010-10-13
ATE476433T1 (de) 2010-08-15
US20130184312A1 (en) 2013-07-18
DK2206711T3 (da) 2012-10-08
US9145404B2 (en) 2015-09-29
PL2311832T3 (pl) 2013-01-31
SI2206711T1 (sl) 2012-12-31
CN102174046A (zh) 2011-09-07
DE602007008212D1 (de) 2010-09-16
CA2725698C (en) 2013-06-18
JP4182363B2 (ja) 2008-11-19
RU2009147223A (ru) 2011-06-27
US8993601B2 (en) 2015-03-31
KR101482374B1 (ko) 2015-01-14
BRPI0706224A2 (pt) 2011-03-22
RU2441002C2 (ru) 2012-01-27
IL214253A (en) 2014-01-30
IL192237A (en) 2013-06-27
KR101118943B1 (ko) 2012-02-27
MY143808A (en) 2011-07-15
KR20100127886A (ko) 2010-12-06
PT1999128E (pt) 2011-01-20
ZA200805235B (en) 2010-07-28
EP1999128A1 (en) 2008-12-10
KR20080077260A (ko) 2008-08-21
KR101252994B1 (ko) 2013-04-15
CN102174044A (zh) 2011-09-07
EP2311833A1 (en) 2011-04-20
CA2634100C (en) 2011-08-23
US20100222590A1 (en) 2010-09-02
DK2311832T3 (da) 2012-10-08
PL2206711T3 (pl) 2013-01-31
HK1159080A1 (en) 2012-07-27
KR20110135427A (ko) 2011-12-16
WO2007119496A1 (en) 2007-10-25
US8501949B2 (en) 2013-08-06
EP1999128B1 (en) 2010-08-04
PH12015502374A1 (en) 2017-03-22
AU2007239906A1 (en) 2007-10-25
CN101365697A (zh) 2009-02-11
RU2008127324A (ru) 2010-01-10
CA2634100A1 (en) 2007-10-25
EP2311832B1 (en) 2012-08-22
IL192237A0 (en) 2009-02-11
TW200813041A (en) 2008-03-16
KR101168630B1 (ko) 2012-07-30
CY1113263T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
NZ564696A (en) Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TW200833675A (en) Nicotinamide derivatives
NO20050828L (no) lndol-3-svovelderivater
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
MX2008012017A (es) Pirazoles como inhibidores de 11-beta-hsd1.
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
TW200612948A (en) 2-substituted heteroaryl compounds
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
MY148634A (en) Pyridazinone derivatives
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
NO20082496L (no) Pyrazinderivater
NO20082445L (no) Neuropeptid-2 reseptor-agonister
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
CY1111574T1 (el) Παραγωγα βουτανοϊκου οξεος, διαδικασιες για την παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και θεραπευτικες εφαρμογες αυτων

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application